Effectiveness of transitioning from omalizumab to dupilumab in chronic spontaneous urticaria patients with inadequate response to omalizumab.

ABSTRACT: Dupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear. This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose Urticaria Control Test (UCT) scores remained <12 after receiving at least 4 doses of omalizumab. Patients were transitioned to dupilumab after inadequate response to omalizumab. UCT scores were assessed at baseline, and 1 and 4 months after starting dupilumab. Laboratory parameters including eosinophil and basophil counts, total IgE, C-reactive protein, and anti-thyroid peroxidase antibody levels were also evaluated. The mean UCT score at the initiation of dupilumab was 6.5 ± 2.2, improving to 8.4 ± 3.0 at 1 month (P = 0.016) and 8.1 ± 3.9

SUBMITTER: Hayama K 

PROVIDER: S-EPMC12355504 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature